Quantbot Technologies LP Decreases Stock Holdings in GSK PLC Sponsored ADR $GSK

Quantbot Technologies LP lessened its holdings in GSK PLC Sponsored ADR (NYSE:GSK) by 83.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 23,397 shares of the pharmaceutical company’s stock after selling 115,501 shares during the period. Quantbot Technologies LP’s holdings in GSK were worth $1,010,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Bard Financial Services Inc. boosted its position in GSK by 17.4% during the 3rd quarter. Bard Financial Services Inc. now owns 158,145 shares of the pharmaceutical company’s stock worth $6,826,000 after purchasing an additional 23,400 shares during the period. Brighton Jones LLC purchased a new position in GSK in the fourth quarter valued at about $528,000. Fisher Asset Management LLC lifted its stake in shares of GSK by 4.4% during the second quarter. Fisher Asset Management LLC now owns 31,338,405 shares of the pharmaceutical company’s stock worth $1,203,395,000 after purchasing an additional 1,306,590 shares in the last quarter. Great Lakes Advisors LLC lifted its stake in shares of GSK by 54.0% during the third quarter. Great Lakes Advisors LLC now owns 49,279 shares of the pharmaceutical company’s stock worth $2,127,000 after purchasing an additional 17,273 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of GSK by 37.6% in the second quarter. SG Americas Securities LLC now owns 25,921 shares of the pharmaceutical company’s stock worth $995,000 after buying an additional 7,081 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Plc Gsk bought 1,470,000 shares of the stock in a transaction dated Thursday, December 11th. The stock was bought at an average cost of $19.00 per share, with a total value of $27,930,000.00. Following the completion of the acquisition, the insider owned 18,245,691 shares of the company’s stock, valued at $346,668,129. This trade represents a 8.76% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.00% of the stock is currently owned by insiders.

GSK Stock Down 1.3%

GSK stock opened at $54.55 on Friday. The firm has a fifty day moving average price of $53.91 and a two-hundred day moving average price of $47.76. The company has a debt-to-equity ratio of 0.92, a current ratio of 0.82 and a quick ratio of 0.54. GSK PLC Sponsored ADR has a 1-year low of $32.38 and a 1-year high of $61.69. The firm has a market cap of $111.18 billion, a price-to-earnings ratio of 14.74, a PEG ratio of 3.34 and a beta of 0.44.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 9th. Shareholders of record on Friday, February 20th will be issued a $0.4856 dividend. This is an increase from GSK’s previous quarterly dividend of $0.42. This represents a $1.94 dividend on an annualized basis and a yield of 3.6%. The ex-dividend date of this dividend is Friday, February 20th. GSK’s dividend payout ratio is 51.62%.

Wall Street Analysts Forecast Growth

GSK has been the subject of a number of recent research reports. HSBC reiterated a “reduce” rating on shares of GSK in a research note on Wednesday, December 10th. Wall Street Zen cut GSK from a “strong-buy” rating to a “buy” rating in a report on Saturday. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a research report on Wednesday, January 14th. TD Cowen reiterated a “hold” rating on shares of GSK in a research note on Monday, February 9th. Finally, Citigroup reissued a “neutral” rating on shares of GSK in a research report on Monday, February 9th. Two investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $44.13.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.